Skip Nav Destination
Close Modal
Search Results for
dipeptidyl
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Book Series
Date
Availability
1-20 of 119 Search Results for
dipeptidyl
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
Book Chapter
Series: Advances in Oto-Rhino-Laryngology
Volume: 45
Published: 05 December 1990
10.1159/000418943
EISBN: 978-3-318-03149-2
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
EISBN: 978-3-318-02674-0
..., Kaufman JM, Ryden M, Muller S, Hanisch FG, Ruige J, Arner P, Sell H, Eckel J: Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60:1917-1925. 9. Sell H, Blüher M, Klöting N, Schlich R, Willems M, Ruppe F, Knoefel W, Dietrich A, Arner P...
Book Chapter
Series: Contributions to Nephrology
Volume: 185
Published: 26 May 2015
EISBN: 978-3-318-05465-1
... peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012;14:762-767. 3. Kim YG, Hahn S, Oh TJ, et al: Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4...
Book Chapter
Book: Novelties in Diabetes
Series: Endocrine Development
Volume: 31
Published: 27 January 2016
10.1159/000439372
EISBN: 978-3-318-05639-6
... comprise injectable GLP-1 receptor agonists and orally active dipeptidyl peptidase-IV inhibitors. Both have a low hypoglycaemia risk. GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, dulaglutide, albiglutide) reduce glycated haemoglobin levels more effectively than oral antidiabetic agents do...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
10.1159/000360560
EISBN: 978-3-318-02674-0
... dipeptidyl peptidase-4, visfatin and lipocalin-2. On the other hand, we summarize the most recent findings on the novel cardioprotective adipokines omentin and apelin. In the context of obesity, adipose tissue (AT) has gained considerable interest as a key player in the pathogenesis of several major...
Book Chapter
Series: Contributions to Nephrology
Volume: 185
Published: 26 May 2015
10.1159/000380974
EISBN: 978-3-318-05465-1
... because the patients' reduced glomerular filtration rate results in the accumulation of certain drugs and/or their metabolites. Although recommended oral antidiabetic agents for patients with CKD differ between countries, all of the currently available dipeptidyl peptidase-4 (DPP-4) inhibitors can be used...
Book Chapter
Book: Novelties in Diabetes
Series: Endocrine Development
Volume: 31
Published: 27 January 2016
EISBN: 978-3-318-05639-6
... hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744. 4. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475730
EISBN: 978-3-318-05974-8
... of these metabolic functions has led to the notion that incretin hormones, and specifically GLP-1, would represent ideal antidiabetic treatment options. As native GLP-1 is degraded by dipeptidyl peptidase type 4 (DPP-4) within minutes, other pharmacological approaches to exploit GLP-1 actions for the treatment...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
10.1159/000360598
EISBN: 978-3-318-02674-0
.... In this chapter, we will discuss the potential mechanisms and current understanding of CV and CBV benefits of native glucagon-like peptide (GLP)-1, GLP-1 receptor agonists and analogues, and of dipeptidyl peptidase-4 inhibitor therapies as a means to better understand differences in safety and efficacy...
Book Chapter
Series: Frontiers in Diabetes
Volume: 22
Published: 10 April 2014
10.1159/000357249
EISBN: 978-3-318-02598-9
.... Periodic screening for diabetes after transplantation is recommended for all transplant recipients, and management of hyperglycemia should be intensive and started right after diagnosis. Treatment choices include insulin, metformin, meglitinide derivatives and dipeptidyl peptidase 4 inhibitors...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
EISBN: 978-3-318-02674-0
... therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012;14:675-688. 4. Monami M, Dicembrini I, Martelli D, Mannucci E: Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(suppl 3):57-64. 5...
Book Chapter
Series: Frontiers in Diabetes
Volume: 19
Published: 12 August 2008
10.1159/000152022
EISBN: 978-3-8055-8641-2
...: dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic peptide. The DPP-4 inhibitors sitagliptin and vildagliptin are orally active and have been shown to be efficacious and safe. They reduce hemoglobin A1c...
Book Chapter
Series: Frontiers in Diabetes
Volume: 19
Published: 12 August 2008
10.1159/000152023
EISBN: 978-3-8055-8641-2
... Abstract Recently we have discovered that the incretin hormone glucagon-like peptide-1 (GLP-2) is an important mediator of cell migration and that GLP-2 is also able to increase proliferation of colon cancer cells. We found that dipeptidyl peptidase IV inhibitors - thought to be a treatment...
Book Chapter
Series: Advances in Cardiology
Volume: 45
Published: 14 February 2008
10.1159/000115193
EISBN: 978-3-8055-8428-9
... disease. New possibilities are representedby incretin mimetic compounds, dipeptidyl peptidase (DPP)-4 inhibitors, inhaled insulinand eventually oral insulin. ...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
EISBN: 978-3-318-05974-8
...:272-279. 45. Lee SA, et al: CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:2553-2561. 46. Yazbeck R, Howarth GS, Abbott CA: Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends...
Book Chapter
Series: Frontiers in Diabetes
Volume: 27
Published: 18 June 2019
10.1159/000486263
EISBN: 978-3-318-06507-7
..., such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose co-transporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, were used. There are 5 large randomized clinical trials that examine the impact of intensive glycaemic control on cardiovascular events in diabetes (Table 1...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475731
EISBN: 978-3-318-05974-8
..., cardioprotective and anti-inflammatory effects. Experimental approaches and treatment of patients with GLP-1 analogs as well as dipeptidyl peptidase-IV (DPP-4) inhibitors, which inhibit the endopeptidase that rapidly degrades GIP and GLP-1, underscore the multiple beneficial effects mediated by GLP-1, beyond blood...
Book Chapter
Series: Forum of Nutrition
Volume: 63
Published: 10 December 2009
EISBN: 978-3-8055-9301-4
...-417 42. Drucker DJ, Nauck MA: The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705 43. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR: Human distribution and release...
Book Chapter
Series: Forum of Nutrition
Volume: 63
Published: 10 December 2009
10.1159/000264393
EISBN: 978-3-8055-9301-4
... is rapidly inactivated by DPP-IV (dipeptidyl peptidase-4) having a half-life in the order of magnitude of seconds. Due to its short half-life, native GLP-1 is consequently not feasible for long-term clinical use. Because of this, novel classes of pharmaceutical agents have been developed that are suitable...
Book Chapter
Series: Frontiers in Diabetes
Volume: 22
Published: 10 April 2014
10.1159/000357248
EISBN: 978-3-318-02598-9
... be monitored for hyperglycemia. Diabetes mellitus should be managed by initiation of medical therapy with metformin and staged treatment intensification with a dipeptidyl peptidase-4 inhibitor, with a switch to a GLP-1 receptor agonist and initiation of insulin, as required, to achieve and maintain glycemic...
1